{1}
##LOC[OK]##
{1}
##LOC[OK]##
##LOC[Cancel]##
{1}
##LOC[OK]##
##LOC[Cancel]##
Explore
About PCEC
PCEC Educational Programs
Medical Advisory Board
Mission Statement
Educational Supporters
Recent Projects
Contact
Survey
NPACE Enduring Pre
Which biomarker hybrid ratio is a plasma measure to support biomarker evaluation of Alzheimer’s disease pathology?
[ Required ]
p-tau217/Aß 42
p-tau181/Aß 42
t-tau/Aß 42
Aß 42/40
Which statement about amyloid-targeting therapies (ATTs) and amyloid-related imaging abnormalities (ARIA) is most accurate?
[ Required ]
ApoE testing is not recommended before starting ATTs because it does not affect ARIA risk
ARIA-E includes microhemorrhage, macrohemorrhage, and superficial siderosis
ApoE testing is recommended before starting ATTs because ApoE e4 carriers have increased ARIA risk
ARIA-H is observed on MRI as vasogenic cerebral edema or sulcal effusion
How confident do you feel in your answer to the previous question?
[ Required ]
Select...
Very confident
Confident
Somewhat confident
Not confident
A 74-year-old woman presents with a 1-year history of increasing forgetfulness. Her spouse reports missed bills and missed routine appointments. In a busy primary care clinic, you want a brief, patient-administered screening tool that requires no training and takes ~2–3 minutes. What is the best choice?
[ Required ]
IQCODE
MMSE
MoCA
Mini-Cog
A 73-year-old man with Medicare insurance has persistent memory concerns and an abnormal cognitive screen. You are considering next steps to support an accurate diagnosis of early symptomatic AD. Which approach best aligns with the “clinical-neuropathologic diagnosis” framework for AD?
[ Required ]
Diagnose AD based on cognitive testing
Order biomarker testing (e.g., plasma or CSF testing) to confirm AD
Combine clinical evaluation with biomarker evaluation to confirm AD
Defer biomarker evaluation and cognitive testing until after specialist consultation
72-year-old man with early symptomatic AD is receiving an amyloid-targeting therapy (ATT). After a recent infusion, the patient develops new dizziness, confusion, and gait disturbance. What is the most appropriate next step?
[ Required ]
Reassure the patient that this is expected and continue therapy as planned
Suspect amyloid-related imaging abnormalities (ARIA); obtain a brain MRI and coordinate holding therapy as needed
Start a cholinesterase inhibitor as soon as possible because this represents disease progression
Discontinue all cognitive medications permanently due to a persistent increased risk of seizures
Submit